#### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 3

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 3 April 13, 2017

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

SHIP OF Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement PROVECTUS BIOPHARMACEUTICALS, INC. Horowitz Bruce (Month/Day/Year) [PVCT] 04/03/2017 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 7327 OAK RIDGE (Check all applicable) HIGHWAY,, SUITE A (Street) 6. Individual or Joint/Group X Director 10% Owner Officer Other Filing(Check Applicable Line) (give title below) (specify below) \_X\_ Form filed by One Reporting Person KNOXVILLE, TNÂ 37931 Form filed by More than One Reporting Person (City) (Zip) Table I - Non-Derivative Securities Beneficially Owned (State) 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Ownership (Instr. 4) Beneficially Owned Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (Instr. 5) Â Common Stock D 1,392,243 Common Stock 50,000 Ι By spouse Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	

#### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Common Stock Warrants (right to buy)	(1)	10/23/2018	Common Stock	100,000	\$ 1	D	Â
Common Stock Warrants (right to buy)	(1)	12/31/2018	Common Stock	100,000	\$ 2	D	Â
Common Stock Warrants (right to buy)	(1)	12/31/2018	Common Stock	400,000	\$ 1	D	Â
Common Stock Warrants (right to buy)	(1)	06/19/2020	Common Stock	400,000	\$ 0.85	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b>F8</b>	Director 10% Owner		Officer	Othe	
Horowitz Bruce 7327 OAK RIDGE HIGHWAY, SUITE A KNOXVILLE, TN 37931	ÂX	Â	Â	Â	

# **Signatures**

/s/ Bruce
Horowitz

\*\*Signature of Reporting Person

O4/13/2017

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The common stock warrants are exercisable currently.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2